Application of diffusion weighted imaging in the diagnosis and treatment of nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2017.10.012

Abstract

Abstract: The judgment of early curative effect is important to the treatment of nasopharyngeal carcinoma and the prognosis of the patients. As a rapid imaging technique, magnetic resonance diffusion weighted imaging (DWI) is used to quantitatively analyze the changes of water molecules in the tissue by means of apparent diffusion coefficient (ADC), so as to diagnose the small lesions of nasopharyngeal carcinoma accurately, evaluate the early curative effect and observe the prognosis. With the continuous improvement and progress of MRI and data analysis technology, DWI in the diagnosis and treatment of nasopharyngeal carcinoma shows a broader application prospect.

Key words: Nasopharyngeal neoplasms, Diffusion magnetic resonance imaging, Diagnosis, Therapy, Apparent diffusion coefficient

Xu Jinpeng, Ren Ruimei, Liu Xiguang, Zhou Jing, Liu Zhicheng. Application of diffusion weighted imaging in the diagnosis and treatment of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2017, 44(10): 771-774.

References

［1］ Chong VH, Ong CK. Nasopharyngeal carcinoma［J］. Eur J Radiol, 2008, 66(3): 437447. DOI: 10.1016/j.ejrad.2008.03.029. ［2］ Yu X, Ren R, Liu S, et al. Application and advances of diffusionweighted imaging in diagnosis and treatment of breast cancer［J］. Zhonghua Zhong Liu Za Zhi, 2014, 36(10): 721725. ［3］ Yokota H, Sakai K, Tazoe J, et al. Clinical feasibility of simultaneous multislice imaging with blippedCAIPI for diffusionweighted imaging and diffusiontensor imaging of the brain［J］. Acta Radiol, 2017, In press. DOI: 10.1177/0284185117692171. ［4］ Mihai PG, Otto M, Domin M, et al. Brain imaging correlates of recovered swallowing after dysphagic stroke: a fMRI and DWI study［J］. Neuroimage Clin, 2016, 12(12): 10131021. DOI: 10.1016/j.nicl.2016.05.006. ［5］曹诗林, 李莹, 徐坚民, 等. 磁共振扩散加权成像在评估鼻咽癌放射治疗中的应用［J］. 实用放射学杂志, 2010, 26(6): 795796. DOI: 10.3969/j.issn.10021671.2010.06.007. ［6］ Fong D, Bhatia KS, Yeung D, et al. Diagnostic accuracy of diffusionweighted MR imaging for nasopharyngeal carcinoma, head and neck lymphoma and squamous cell carcinoma at the primary site［J］. Oral Oncol, 2010, 46(8): 603606. DOI: 10.1016/j.oraloncology.2010.05.004. ［7］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228247. DOI: 10.1016/j.ejca.2008.10.026. ［8］龚唯, 周菊英, 吴琼, 等. MRI成像对鼻咽癌的分期、诊断及治疗优势的探讨［J］. 肿瘤防治研究, 2012, 39(4): 455459. DOI: 10.3971/j.issn.10008578.2012.04.023. ［9］ Varoquaux A, Rager O, Lovblad KO, et al. Functional imaging of head and neck squamous cell carcinoma with diffusionweighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV［J］. Eur J Nucl Med Mol Imaging, 2013, 40(6): 842852. DOI: 10.1007/s0025901323519. ［10］朱培杨, 周玮, 黄小燕, 等. MR扩散加权成像在鼻咽良恶性病变及鼻咽癌T分期中的诊断价值［J］. 中国现代医生, 2014, 52(36): 5558. ［11］ Li H, Wang DL, Liu XW, et al. MRI signal changes in the skull base bone after endoscopic nasopharyngectomy for recurrent NPC: a serial study of 9 patients［J］. Eur J Radiol, 2013, 82(2): 309315. DOI: 10.1016/j.ejrad.2012.10.022. ［12］ Yuan J, Yeung DK, Mok GS, et al. NonGaussian analysis of diffusion weighted imaging in head and neck at 3T: a pilot study in patients with nasopharyngeal carcinoma［J］. PLoS One, 2014, 9(1): 8724. DOI: 10.1371/journal.pone.0087024. ［13］ Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusionweighted MR imaging for nodal staging［J］. Radiology, 2009, 251(1): 134146. DOI: 10.1148/radiol.2511080128. ［14］ Lai V, Khong PL. Updates on MR imaging and 18FFDG PET/CT imaging in nasopharyngeal carcinoma［J］. Oral Oncol, 2014, 50(6): 539548. DOI: 10.1016/j.oraloncology.2013.05.005. ［15］ Abdel Razek AA, Kamal E. Nasopharyngeal carcinoma: correlation of apparent diffusion coefficient value with prognostic parameters［J］. Radiol Med, 2013, 118(4): 534539. DOI: 10.1007/s115470120890x. ［16］ Zhang GY, Wang YJ, Liu JP, et al. Pretreatment diffusionweighted MRI can predict the response to neoadjuvant chemotherapy in patients with nasopharyngeal carcinoma［J］. Biomed Res Int, 2015, 2015: 307943. DOI: 10.1155/2015/307943. ［17］ Hong J, Yao Y, Zhang Y, et al. Value of magnetic resonance diffusionweighted imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma［J］. Otolaryngol Head Neck Surg, 2013, 149(5): 707713. DOI: 10.1177/0194599813496537. ［18］ King AD, Chow KK, Yu KH, et al. Head and neck squamous cell carcinoma: diagnostic performance of diffusionweighted MR imaging for the prediction of treatment response［J］. Radiology, 2013, 266(2): 531538. DOI: 10.1148/radiol.12120167. ［19］柳善刚, 任瑞美. 弥散加权成像在肿瘤疗效监测和评估中的应用及进展［J］. 中华临床医师杂志(电子版), 2015, 9(2): 327328. DOI: 10.3877/cma.j.issn.16740785.2015.02.033. ［20］林蒙, 余小多, 罗德红, 等. MR扩散加权成像预测鼻咽癌患者同步放化疗疗效的可行性［J］. 中华放射学杂志, 2014, 48(6): 467471. DOI: 10.3760/cma.j.issn.10051201.2014.06.007. ［21］ Chen Y, Liu X, Zheng D, et al. Diffusionweighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma［J］. Magn Reson Imaging, 2014, 32(6): 630637. DOI: 10.1016/j.mri.2014.02.009. ［22］李伟, 彭俊琴, 卢斌贵, 等. 不同ADC值及标准差在评估鼻咽癌近期疗效中的比较［J］. 广东医学, 2016, 37(21): 32173220. DOI: 10.3969/j.issn.10019448.2016.21.020. ［23］ Ji C, Zhang Q, Guan W, et al. Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers［J］. Oncotarget, 2017, 5(2): 110. DOI: 10.18632/oncotarget.17570.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.